Fenethylline, also known by the trade name Captagon, is a synthetic psychoactive stimulant that has recently been linked to a substanceuse disorder and 'pharmacoterrorism' in the Middle East 1-4 . Although fenethylline shares a common phenethylamine core with other amphetamine-type stimulants, it also incorporates a covalently linked xanthine moiety into its parent structure 5,6 . These independently active pharmacophores are liberated during metabolism, resulting in the release of a structurally diverse chemical mixture into the central nervous system 7-9 . Although the psychoactive properties of fenethylline have been reported to differ from those of other synthetic stimulants, the in vivo chemical complexity it manifests upon ingestion has impeded efforts to unambiguously identify the specific species responsible for these effects 10,11 . Here we develop a 'dissection through vaccination' approach, called DISSECTIV, to mitigate the psychoactive effects of fenethylline and show that its rapid-onset and distinct psychoactive properties are facilitated by functional synergy between theophylline and amphetamine. Our results demonstrate that incremental vaccination against a single chemical species within a multi-component mixture can be used to uncover emergent properties arising from polypharmacological activity. We anticipate that DISSECTIV will be used to expose unidentified active chemical species and resolve pharmacodynamic interactions within other chemically complex systems, such as those found in counterfeit or illegal drug preparations, post-metabolic tissue samples and natural product extracts.
vaccination for the treatment of drug abuse, where a small-molecule hapten-protein conjugate is delivered with the intention of generating antibodies that sequester the target drug in the periphery, preventing induction of central nervous system (CNS)-mediated effects 21 . A 'dynamic' variant of this general approach was recently developed to blunt heroin self-administration, for which a single chemically labile hapten was used to induce antibodies directed against multiple opioid metabolites 22 . These foundational studies inspired us to pursue a generalizable 'dissection through vaccination' method that could isolate the effects of single compounds within a structurally and pharmacologically diverse chemical system, such as that generated by fenethylline [7] [8] [9] . We termed the resulting approach 'Determining the Identities of Species Supporting Expression of CNS-activity Through Incremental Vaccination' (DISSECTIV) (Extended Data Fig. 1 ).
Our chemical strategy for synthesizing the parent fenethylline hapten was informed by the knowledge that fenethylline (1) generates metabolites 2-5, including amphetamine (2) and substituted-theophylline metabolites, which are further processed to theophylline (6) following oxidative metabolism by cytochrome P450 (CYP450) enzymes (Fig. 1a ). We therefore installed our linker on the amphetamine-associated nitrogen that separates the two carbons where oxidation produces metabolites 2-5. Starting from 6, we first performed an N-alkylation with 1-chloro-2-iodoethane to generate 7, which was subjected to an in situ Finkelstein reaction and a second N-alkylation with 2 to generate 1. The final hapten species (FEN, 8) was generated from the condensation of 1 with glutaric anhydride with a 24% overall yield ( Fig. 1b and Supplementary Methods). This hapten was conjugated to keyhole limpet haemocyanin (KLH) using sulfo-N-hydroxysuccinimide in phosphate buffered saline (PBS) to generate the immunogenic species for vaccination, termed FEN-KLH. A separate conjugation to bovine serum albumin (BSA) was carried out to generate FEN-BSA for in vitro analyses (Extended Data Fig. 2) .
To prepare the vaccine formulation, FEN-KLH was combined with two adjuvants, alum and CpG 1826. Intraperitoneal administration of the vaccine to Swiss Webster mice on days 0, 14 and 28 generated robust antibody midpoint titres (Fig. 1c ). Competitive surface plasmon resonance was then used to measure the relative binding strength of antibodies generated from FEN-KLH vaccination against fenethylline and its active metabolites. In these assay conditions, the binding of fenethylline was strongest, followed by theophylline, then amphetamine ( Fig. 1d ). Complementary use of an enzyme-linked immunosorbent assay to assess antibody specificity confirmed that antibodies within FEN-KLH serum were able to recognize the general structure of all three compounds ( Fig. 1e ). To further explore the functional antibody-binding profile of FEN-KLH in an immediately relevant model, we measured whether vaccination could alter the pharmacokinetics of fenethylline, theophylline and amphetamine in vivo, using liquid chromatography-mass spectrometry analysis to quantify drug concentrations (Extended Data Fig. 3 ). Notably, when the effect of vaccination on drug disposition was assessed over time after intraperitoneal administration, FEN-KLH binding was indeed found to be sufficient to increase peak fenethylline, theophylline and amphetamine sequestration in the periphery due to the binding of drug-specific antibodies ( Fig. 1f ). As anticipated, this peripheral binding ultimately led to reductions in the rapid distribution of these compounds into the CNS (Fig. 1g ).
We also assessed whether endophenotypes relevant to fenethylline abuse could be blocked by FEN-KLH in a number of animal models. When control animals were given fenethylline in an open-field, hyperlocomotor activity assay, a clear dose-dependent increase in locomotor activity was observed, and this effect was significantly diminished in FEN-KLH-vaccinated animals ( Fig. 2a-c ). Furthermore, we used an elevated plus maze (EPM) assay to measure anxiety-related behaviours following drug administration, as recent reports of fenethylline use in Syria have noted its apparent ability to induce hypervigilance, a behaviour that is associated with persistent anxiety states in humans 23, 24 . In this experiment, fenethylline reduced the time that control animals spent in the open arms of the apparatus, whereas no such change was found in animals that had been vaccinated with FEN-KLH ( Fig. 2d, e ). In addition, because fenethylline demonstrates rewarding effects in human users, we assessed whether it could induce a conditioned place preference (CPP). We found that training with fenethylline could indeed induce CPP and observed that FEN-KLH showed a trend towards blockade of this effect, although efficacy was variable ( Fig. 2f ). Importantly, vaccination with FEN-KLH was able to decrease the pharmacodynamic effects of amphetamine and methamphetamine alone, which are both often found alongside theophylline and caffeine in counterfeit tablets 17 (Extended Data Fig. 4) .
Because FEN-KLH demonstrated binding to fenethylline and its active metabolites, its blockade of stimulant effects could not be attributed to perturbation of one specific chemical species. Therefore, we used our DISSECTIV approach to identify the compound(s) supporting the overall psychoactivity of fenethylline. The presence of the letter reSeArCH distinct psychoactive effects of fenethylline, as compared to amphetamine alone, imply that either the parent drug has unique activity or that the combined activities of the metabolites act together to produce an altered response 9, 10 . Notably, the fenethylline structure itself demonstrated little binding at 10 μ M across a suite of 31 CNS targets, so we prioritized exploration of how active metabolites of fenethylline contribute to its unique psychoactive profile (Extended Data Table 1 ). Therefore, a theophylline hapten (THEO, 9) and two amphetamine haptens (AMPH, 10; 1-A 1, 11) were generated 25 ( Fig. 3a and Supplementary Methods). Following formulation and immunization with these haptens, robust titres were observed for THEO-KLH and 1-A 1 -KLH ( Fig. 3b ). While THEO-KLH serum readily bound theophylline and fenethylline, but not amphetamine, 1-A 1 -KLH bound amphetamine and fenethylline, but not theophylline ( Fig. 3c, d) . The same pattern of binding activity was observed for in vivo serum measurements ( Fig. 3e-g) . By contrast, AMPH-KLH generated ineffective antibodies, despite its structural similarity to the previously reported hapten SMA-KLH 26 (Extended Data Fig. 5 ). While THEO-KLH had a relatively minor impact on total distance travelled in the hyperlocomotor assay, 1-A 1 -KLH vaccination substantially decreased fenethyllineinduced activity (Fig. 3h , i). This indicated that amphetamine was a major component of the stimulant behaviour of fenethylline. Similarly, the activity of fenethylline in the EPM assays was found to be substantially blunted by 1-A 1 -KLH, but not by THEO-KLH ( Fig. 3j, k) . The CPP data again showed a trend towards 1-A 1 -KLH being slightly more effective than THEO-KLH, although the efficacy was variable, similar to FEN-KLH ( Fig. 3l ). Although the impact of vaccination with 1-A 1 -KLH was more obvious across the entire set of behavioural testing, vaccination with THEO-KLH did appear to weakly blunt the behavioural effects of fenethylline overall, implying that theophylline has a supportive, rather than antagonistic, role in modulating these amphetamine-driven effects of fenethylline.
Notably, during further analysis of the hyperlocomotor behaviour induced by fenethylline, the onset of its stimulant activity was found to be more rapid than that of amphetamine alone (Fig. 4a ). However, the penetration of amphetamine into brain tissue following release from fenethylline lags behind that of directly administered amphetamine (Fig. 4b ). This disparity further implicated a potential polypharmacological basis for stimulant activity, and indeed, when otherwise ineffective doses of theophylline and amphetamine were administered together, the total locomotor response was potentiated ( Fig. 4c ). Furthermore, this synergistic stimulant effect was observed for other xanthine/phenethylamine combinations, opposing the earlier concept that coliberation of these two classes of drugs would uniformly improve the risk/benefit profile of fenethylline ( Fig. 4d ). These findings instead support the emergence of an altered subjective stimulant experience generated by coincident alteration of adenosinergic and dopaminergic signalling, thus providing a plausible explanation for why militant groups are motivated to expend additional effort to incorporate xanthines into counterfeit products, instead of amphetaminetype stimulants alone 27, 28 .
Overall, by using FEN-KLH, THEO-KLH, and 1-A 1 -KLH as chemical neuroscience tools in our DISSECTIV approach, we have reconciled previously conflicting data regarding the underlying pharmacology driving the psychoactive profile of fenethylline. Its prominent stimulant features can be attributed to amphetamine, with synergistic support from theophylline, and no direct contributions from the parent drug molecule (Extended Data Table 2 ). These results have direct relevance for the study of other poorly understood, yet clinically applied, covalent theophylline conjugates, such as cafedrine and theodrenaline 29 . Furthermore, our findings implicate the use of amphetamine-and theophylline-binding haptens, including FEN and 1-A 1 , as efficacious and potentially complementary vaccination strategies to blunt the pharmacodynamic effects of fenethylline, a synthetic drug whose abuse is undergoing conflict-driven global expansion. Perhaps most importantly, we expect that this 'dissection through vaccination' strategy can be broadly applied to numerous other complex chemical systemsincluding natural product extracts, synthetic psychoactive drugs and post-metabolic tissue samples-in order to illuminate unexpected polypharmacological interactions and identify the exact chemical origin for each component within a multi-faceted pharmacodynamic profile. letter reSeArCH MethOdS Animals. Animal studies were approved by TSRI's Institutional Care and Use Committee and carried out according to NIH guidelines. Male Swiss Webster mice (Taconic Biosciences, 6-8 weeks old) were used for all studies, and housed four per cage in a temperature-controlled (22 °C) vivarium on a reversed 12-h light cycle (21:00-09:00) with ad libitum access to food and water. Animals were randomly assigned to their experimental groups with stratification to use littermates as controls. The experimenter was blinded to group identity during data processing, and behavioural results were automatically scored using AnyMAZE v.4.99 (Stoelting Co). Drugs. Theophylline, amphetamine hemisulfate and methamphetamine hydrochloride (> 95%, Sigma-Aldrich) were obtained commercially. Fenethylline (> 95%) was synthesized and purified at TSRI. Amphetamine-d 11 , fenethylline-d 3 (Lipomed) and theophylline-d 6 (CDN Isotopes) were obtained commercially for use as liquid chromatography-mass spectrometry (LC-MS) internal standards. For in vivo studies, all drugs were dosed intraperitoneally at a volume load of 10 ml kg −1 in bacteriostatic saline (0.9% w/v). Chemical analysis. Details of chemical synthesis, characterization and relevant spectra are included in the Supplementary Methods. Hapten conjugation and vaccination. Conjugation of haptens 8-11 to carrier proteins was performed as previously reported 30 . Each hapten-KLH conjugate was combined with alum (Invivogen) and CpG 1826 (Eurofins Genomics) and shaken for 20 min before injection. Animals were immunized by intraperitoneal injection on study days 0, 14 and 28 with a vaccine formulation containing 50 μ g of hapten, 1 mg of alum and 50 μ g of CpG 1826 in 125 μ l of sterile-filtered PBS (pH 7.4). Antibody binding. ELISA analyses were carried out as previously described using horseradish peroxidase donkey-anti-mouse IgG (Jackson Immunoresearch, 715-035-151) 26, 30 . Surface plasmon resonance experiments were conducted on a Biacore 3000 (GE Healthcare) equipped with a research-grade CM4 sensor chip. BSA and the hapten-BSA conjugates were immobilized using NHS/EDC coupling chemistry and dilution or anti-sera was performed to normalize baseline binding across samples. Serum was pre-incubated with compound at room temperature for 30 min, the mixture was injected over the flow cell for 5 min, and dissociated for 2.5 min in running buffer (HBS-EP+ buffer, pH7.4, GE Healthcare) before the surface was regenerated with Gly-HCl, pH 1.5. Behavioural analysis. Vaccinated animals were tested in behavioural models on days 36-42 in a dedicated 4.6 × 4.6 m room. Each individual animal received all drug treatments in a random order over the course of the experiment, with 24-72 h washout periods between. For open-field hyperlocomotion tests, the animals were acclimated for 1 h in a plastic box (267 × 483 × 203 mm) with a clear lid. Mice were then injected and immediately returned to the cage to be recorded for 90 min (45-50 lx). For EPM tests, animals were injected, then immediately placed in the centre of a plastic plus maze (500 mm height) with two open arms (50 × 300 × 3 mm wall) and two closed arms (50 × 300 × 150 mm wall) and tracked for 5 min (120 lx (centre), 85 lx (ends)). The percentage of time spent in the open arms was calculated by: (open arm time/total time) × 100. For the CPP test, all animals were placed in a plastic box (267 × 483 × 203 mm) divided by colour (black versus white walls) and texture (smooth versus textured floor), and tracked for 20 min (13:00; 45-50 lx). On the next day, a wall was placed in between the two chambers. Animals then received saline and were placed in the more-preferred chamber for 20 min (08:00). Later, each animal received drug and was placed in the less-preferred chamber for 20 min (18:00). This training was repeated for three days. Following training, the dividing wall was removed and the animals were tracked for 20 min (13:00). The change in seconds for the drug-paired chamber before and after training was calculated by: (chamber time post training − chamber time pre-training). Pharmacokinetic analysis. On day 49 animals were injected intraperitoneally with test compounds. Blood was taken via the retro-orbital route, brain tissue was flash-frozen using acetone:CO 2 (s). Tissues were stored at − 80 °C until analysis. For serum samples, 20 μ l were added to 80 μ l of methanol + 200 ng internal standard. This was centrifuged for 10 min at 10,000 r.p.m., and 60 μ l were transferred to a LC-MS vial. Fenethylline brain samples were diluted into four volumes of H 2 O, homogenized and 1 ml was placed into 1 ml dichloromethane (DCM) + 200 ng internal standard. This was stirred for 2 h, the DCM was collected, centrifuged as above, dried under vacuum and then resuspended in 60 μ l methanol. Theophylline brain tissue was homogenized in four volumes of H 2 O, and 1 ml + 200 ng internal standard was stirred for 2 h, centrifuged, dried and resuspended as above. Amphetamine brain tissue was homogenized in four volumes of 10 M NaOH, 1 ml was then placed into 1 ml hexane + 200 ng internal standard, stirred for 2 h, and the hexane fraction was counter-extracted into 200 μ l of 0.1 M HCl, dried and resuspended as above. Analysis was carried out on an Agilent 1100 LC-MS system with a Poroshell 120 SB-C8 column using H 2 O/ACN (with 0.1% formic acid) as the mobile phase (5-95% ACN, 10 min gradient). Using the ratio of drug to internal standard integration values, the unknown tissue concentrations were determined using a standard curve for the drug in question. Statistical analysis. Sample sizes were calculated to give > 80% power using means and standard deviations from our previous results for small molecule vaccines. Where 'n' is listed, it represents the number of animals used for analysis. Where 'x replicates' are listed, it represents the number of times the experiment was repeated in the laboratory. Outliers were detected at a predefined level of P < 0.05 using Grubb's outlier test and excluded from analysis. Data were graphed and analysed using Prism 5.02 (GraphPad software), setting P < 0.05 as the critical value. Groups were analysed for similarity of variance using Bartlett's test, and non-parametric tests were used where the data was found to be non-normally distributed. All statistical tests were performed using two-tailed analysis. Data availability. Source Data supporting the findings of this study can be found with the respective figures in the online version of the paper. Additional information can be supplied by the corresponding author upon reasonable request. * P < 0.01 versus KLH, Bonferroni correction). n = 5, repeated-measures two-way ANOVA. b, Methamphetamine (2 mg kg −1 ) locomotor behaviour in animals vaccinated with KLH (n = 9) or FEN-KLH (n = 11) (P interaction = 0.0385; F 30,540 = 1.52; * P < 0.01 versus KLH, Bonferroni correction). Repeated-measures two-way ANOVA. c, EPM in KLHvaccinated animals following saline (n = 9), amphetamine (A., 2 mg kg −1 , n = 10) or methamphetamine (M., 2 mg kg −1 , n = 10) administration. Oneway ANOVA (P = 0.1325; F 2,26 = 2.187). d, EPM in FEN-KLH-vaccinated animals following saline (n = 9), amphetamine (2 mg kg −1 , n = 10) or methamphetamine (2 mg kg −1 , n = 10) administration. One-way ANOVA (P = 0.9588; F 2,26 = 0.042). a, b, Data are presented as mean ± s.e.m. c, d, Data are shown as median with quartiles ± 10-90% CI; + , mean. 
Data exclusions
Describe any data exclusions. One outlier removed each for Figure 2b and 2d, mentioned in legend.
Outliers were detected at a predefined level of p <0.05 using Grubb's Outlier test and excluded from analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
See individual figure legends for the number of biological and technical replicates, listed for each experiment.
Where 'n' is listed, it represents the number of biological replicates used for analysis. Where 'x replicates' is listed, it represents the number of times the experiment was repeated in the laboratory.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Animals were randomly assigned to their experimental groups with stratification to use littermates as controls.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The experimenter was blinded to group identity during data processing, and behavioral results were automatically scored using AnyMAZE v. 4 The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Behavioral results were automatically scored using AnyMAZE v.4.99 (Stoelting Co) Data were graphed and analyzed using Prism 5.02 (GraphPad Software)
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
Theophylline, amphetamine hemisulfate, and methamphetamine hydrochloride (>95%, Sigma Aldrich) were obtained commercially. Fenethylline (>95%) was synthesized and purified at TSRI. Amphetamine-d11, Fenethylline-d3 (Lipomed) and Theophylline-d6 (CDN Isotopes) were obtained commercially for use as LC/MS internal standards (IS).
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
ELISA analyses were carried out as previously described using horseradish peroxidase-donkey-anti-mouse IgG (Jackson Immunoresearch Catalog # 715-035-151).
Antibody activity was validated against control mouse serum containing IgG using a TMB substrate for visualization of HRP activity No eukaryotic cell lines were used
